Today: 27 January 2026
Subscribe
Browse Category

Healthcare Industry News 5 December 2025 - 17 December 2025

Medline IPO: MDLN Debuts on Nasdaq After $6.26 Billion Raise in 2025’s Biggest Global Listing

Medline IPO: MDLN Debuts on Nasdaq After $6.26 Billion Raise in 2025’s Biggest Global Listing

Medline is officially back in the public markets. On Wednesday, December 17, 2025, the Northfield, Illinois-based medical supply powerhouse begins trading on the Nasdaq Global Select Market under the ticker MDLN, following an upsized initial public offering that raised about $6.26 billion—the largest global IPO of 2025. Reuters For Wall Street, the scale of the deal matters. For hospitals and…
17 December 2025
····
Danaher Stock (DHR) News Today: BofA Lifts Price Target to $265, Wells Fargo to $240 as 2026 Normalization Comes Into Focus

Danaher Stock (DHR) News Today: BofA Lifts Price Target to $265, Wells Fargo to $240 as 2026 Normalization Comes Into Focus

Danaher Corporation (NYSE: DHR) is back in the spotlight on Monday, December 15, 2025, after two fresh Wall Street updates pushed Danaher stock back into the “what’s next” conversation for life-science and diagnostics investors. In afternoon trading, DHR hovered around $227 per share, modestly higher on the day. The bigger story isn’t a dramatic price move—it’s the shift in tone…
15 December 2025
····
UnitedHealth Group (UNH) Stock News and Forecasts on Dec. 14, 2025: DOJ-Amedisys Deal, Optum Opioid Lawsuit, Earnings Date, and Analyst Targets

UnitedHealth Group (UNH) Stock News and Forecasts on Dec. 14, 2025: DOJ-Amedisys Deal, Optum Opioid Lawsuit, Earnings Date, and Analyst Targets

Updated: December 14, 2025 UnitedHealth Group Incorporated (NYSE: UNH) is ending the weekend with a rare combination for a Dow heavyweight: a near-term relief catalyst (a key court-approved DOJ settlement tied to the Amedisys deal) alongside fresh legal headline risk (West Virginia’s opioid-related lawsuit targeting Optum). Add an upcoming full-year 2025 earnings release with 2026 guidance in late January, and…
14 December 2025
····
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Updated: December 14, 2025 (Sunday) Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: (1) the EU regulator’s support for a higher-dose Wegovy, (2) the long-telegraphed India launch of Ozempic at a sharply lower price point, and (3) the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand…
14 December 2025
····
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting. After the bell:…
12 December 2025
····
CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

Published: December 12, 2025 CSL Limited stock (ASX: CSL) is back in the spotlight on December 12, 2025, with fresh disclosure showing the company’s on-market share buyback is still running at pace—while investors continue weighing a messy mix of catalysts: vaccine-market volatility, government scrutiny of Australia’s “sovereign manufacturing” deals, and a pipeline story that just landed in The New England…
12 December 2025
····
GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK plc stock has quietly morphed from a problem child of Big Pharma into one of 2025’s more interesting “value with growth” stories. The shares are trading near multi‑year highs, the company has upgraded guidance, big litigation overhangs are easing, and a cluster of U.S. FDA decisions is about to test how much of that optimism is justified. As of…
11 December 2025
···
UnitedHealth Group (UNH) Stock Forecast 2026: Can the Healthcare Giant Recover From 2025’s Crises?

UnitedHealth Group (UNH) Stock Forecast 2026: Can the Healthcare Giant Recover From 2025’s Crises?

Published: December 10, 2025 – All data current as of market close on this date. This article is for informational purposes only and is not investment advice. UnitedHealth Group stock today: A blue chip in the penalty box UnitedHealth Group Incorporated (NYSE: UNH) – long considered one of the steadiest blue chips in U.S. healthcare – is ending 2025 in…
10 December 2025
···
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda and the broader pipeline. As of late trading on December 10, 2025, Merck stock changes hands around $97.27, up slightly…
10 December 2025
····
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable listed company to a bruised turnaround story in 2025. For investors, NVO has abruptly shifted from a “can do no…
7 December 2025
····
Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

As of the close on 5 December 2025, Medtronic plc (NYSE: MDT) stock trades around $101.36–$101.39 per share, giving the medical device giant a market capitalization of roughly $130 billion, a P/E ratio near 27.4, and a dividend yield of about 2.8%. MarketBeat In the first week of December, Medtronic has delivered a flurry of stock‑moving news: a new FDA…
6 December 2025
····
UnitedHealth Group (UNH) Stock on December 5, 2025: Recovery Rally, 2026 Forecasts and the Legal Risks Investors Can’t Ignore

UnitedHealth Group (UNH) Stock on December 5, 2025: Recovery Rally, 2026 Forecasts and the Legal Risks Investors Can’t Ignore

UnitedHealth Group Incorporated (NYSE: UNH) is back in focus after a bruising year that saw the stock plunge to a five‑year low, attract a U.S. Department of Justice investigation, suffer the largest healthcare data breach in U.S. history – and then stage a powerful recovery rally into late 2025. As of the latest quote on December 5, 2025, UNH trades…
5 December 2025
···
1 … 4 5 6 7 8 … 10

Stock Market Today

  • Soybeans Retreat from Early Gains as Export Data Shows Mixed Signals
    January 27, 2026, 1:25 AM EST. Soybean futures dropped 4 to 5 cents on Monday after initial overnight gains, with March contracts at $10.63 per bushel. The national average cash soybean price rose slightly to $9.93 1/4. Export inspections revealed shipments of 1.324 million metric tons last week, down 1.54% from the week before but up nearly 80% year-on-year. China remained the largest destination. Marketing year shipments have increased 37.5% year-on-year. However, recent export sales are 22% below last year, underperforming USDA projections. Speculative traders reduced net long positions by nearly 3,000 contracts, reflecting cautious sentiment. Brazil's harvest is progressing briskly with a crop estimate raised to 181 million metric tons. Soymeal futures fell $3.90 to $4.70, while soy oil futures inched higher, indicating mixed demand pressures across related commodities.
Go toTop